Patents by Inventor Yik Andy Yeung
Yik Andy Yeung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043490Abstract: Provided herein are targeted cytokine constructs and method of engineered cell therapy by administering a targeted cytokine construct in combination with an engineered cell therapy, for use in treating a disease, e.g., a proliferative disease, e.g., a cancer.Type: ApplicationFiled: December 8, 2021Publication date: February 8, 2024Inventors: Ivana DJURETIC, Kelly MOYNIHAN, Wei CHEN, Paul BESSETTE, Christopher KIMBERLIN, Nathan MATHEWSON, Yik Andy YEUNG
-
Publication number: 20240018252Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: August 25, 2023Publication date: January 18, 2024Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20240010695Abstract: Provided herein are mutant interleukin-10 polypeptides, and fusion polypeptides comprising the mutant interleukin-10 polypeptides and antigen binding molecules. The present disclosure provides methods of modulating immune cell function by contacting the immune cell with fusion polypeptides of the present disclosure. In addition, the disclosure also provides polynucleotides encoding the disclosed fusion molecules, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the fusion molecules, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: December 8, 2021Publication date: January 11, 2024Inventors: Yik Andy YEUNG, David LIU, Renee GREER, Henry NGUYEN, Sindy Liao CHAN, Sherman Michael CHIN, Paul MESKO, Irene NI, Ivana DJURETIC
-
Patent number: 11814435Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: GrantFiled: August 27, 2020Date of Patent: November 14, 2023Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
-
Publication number: 20230357343Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.Type: ApplicationFiled: April 26, 2023Publication date: November 9, 2023Inventors: Yik Andy Yeung, Renee L. Greer, Henry C. Nguyen, David Liu, Byong Kang, Ivana Djuretic
-
Publication number: 20230340104Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.Type: ApplicationFiled: April 27, 2023Publication date: October 26, 2023Inventors: Yik Andy Yeung, Renee L. Greer, Henry C. Nguyen, David Liu, Byong Kang, Ivana Djuretic
-
Publication number: 20230181634Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).Type: ApplicationFiled: May 31, 2018Publication date: June 15, 2023Inventors: Barbra Johnson SASU, Danielle Elizabeth DETTLING, Cesar Adolfo SOMMER, Yik Andy YEUNG, Moustafa Marc HAMZE
-
Publication number: 20230059489Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).Type: ApplicationFiled: June 24, 2022Publication date: February 23, 2023Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
-
Patent number: 11421040Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).Type: GrantFiled: May 31, 2018Date of Patent: August 23, 2022Assignee: Pfizer Inc.Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
-
Publication number: 20220251202Abstract: Provided herein are fusion proteins that bind human CD8?, human CD8?, or human PD1 and comprise a mutant IL-2 polypeptide, as well as polynucleotides, host cells, compositions, and methods of use thereof.Type: ApplicationFiled: June 5, 2020Publication date: August 11, 2022Inventors: Ivana DJURETIC, Yik Andy YEUNG
-
Publication number: 20220162314Abstract: Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: October 22, 2021Publication date: May 26, 2022Inventors: Yik Andy YEUNG, Ivana DJURETIC, Paul BESSETTE, Wei CHEN, Sherman Michael CHIN, Kelly Dare MOYNIHAN, Henry C. NGUYEN, Irene NI, Danielle C. PAPPAS, Terrence PARK
-
Patent number: 11155630Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.Type: GrantFiled: December 21, 2020Date of Patent: October 26, 2021Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
-
Publication number: 20210324028Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: ApplicationFiled: June 24, 2021Publication date: October 21, 2021Applicant: Pfizer Inc.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Patent number: 11059876Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: GrantFiled: February 26, 2019Date of Patent: July 13, 2021Assignee: PFIZER INC.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Publication number: 20210188991Abstract: The present invention relates bispecific antibodies that specific binds to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.Type: ApplicationFiled: December 21, 2020Publication date: June 24, 2021Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20210054087Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: August 27, 2020Publication date: February 25, 2021Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20210002359Abstract: Variant immunoglobulins with one or more amino acid modifications in the Fe region that have increased in vivo half-lives, and methods of using the same are provided.Type: ApplicationFiled: June 1, 2020Publication date: January 7, 2021Applicant: Genentech, Inc.Inventors: Henry B. LOWMAN, Yik Andy YEUNG, Lisa A. DAMICO, Napaleone FERRARA, Yu-Ju G. MENG
-
Patent number: 10793635Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: GrantFiled: June 25, 2018Date of Patent: October 6, 2020Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
-
Publication number: 20190263877Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: ApplicationFiled: February 26, 2019Publication date: August 29, 2019Applicant: Pfizer Inc.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Publication number: 20190085094Abstract: Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.Type: ApplicationFiled: November 16, 2018Publication date: March 21, 2019Applicant: Genentech, Inc.Inventors: Yik Andy Yeung, Henry B. Lowman